Profil
Michael K.
Brawer served as Director at Northwest Prostate Institute and Vice President-Medical Affairs at Myriad Genetics, Inc. He was also the Chief Medical Officer at Threshold Pharmaceuticals, Inc. from 2003 to 2007 and the Chief Medical Officer & Executive Vice President at MDxHealth SA from 2017 to 2018.
Brawer received his undergraduate and doctorate degrees from the University of California, Los Angeles.
Anciens postes connus de Michael K. Brawer
| Sociétés | Poste | Fin |
|---|---|---|
| MDXHEALTH SA | Directeur Technique/Scientifique/R&D | 14/12/2018 |
Threshold Pharmaceuticals, Inc.
 Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Directeur Technique/Scientifique/R&D | 02/11/2007 |
| Northwest Prostate Institute | Directeur/Membre du Conseil | - |
| MYRIAD GENETICS, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Michael K. Brawer
| University of California, Los Angeles | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MYRIAD GENETICS, INC. | Health Technology |
| MDXHEALTH SA | Health Technology |
| Entreprise privées | 2 |
|---|---|
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
| Northwest Prostate Institute |
